Research graph
References from Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
COVID-19 deaths and hospitalizations averted by rapid vaccination rollout in the United States
2021 · External reference
Unresolved reference
External reference
Can the USA return to pre-COVID-19 normal by July 4?
10.1016/s1473-3099(21)00324-8 · 2021 · External reference
Social contacts and mixing patterns relevant to the spread of infectious diseases
10.1371/journal.pmed.0050074 · 2008 · External reference
Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK
10.1186/s12916-020-01597-8 · 2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
10.1126/science.abg3055 · 2021 · External reference
Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
10.1038/s41586-021-03426-1 · 2021 · External reference
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
10.1136/bmj.n579 · 2021 · External reference
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
10.1126/science.abh2644 · 2021 · External reference
Unresolved reference
External reference
Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020
10.1001/jamainternmed.2020.7976 · 2021 · External reference
Unresolved reference
2021 · External reference
Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing
10.1126/science.abb6936 · 2020 · External reference
The implications of silent transmission for the control of COVID-19 outbreaks
10.1073/pnas.2008373117 · 2020 · External reference
Infectivity of asymptomatic versus symptomatic COVID-19
10.1016/s0140-6736(20)32651-9 · 2021 · External reference
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
10.1016/j.cell.2021.02.037 · 2021 · External reference
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
10.1038/s41591-021-01318-5 · 2021 · External reference
Coronavirus variants are spreading in India - what scientists know so far
10.1038/d41586-021-01274-7 · 2021 · External reference
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
2021 · External reference
Unresolved reference
2021 · External reference
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
10.1016/s2666-5247(21)00068-9 · 2021 · External reference
Projecting demand for critical care beds during COVID-19 outbreaks in Canada
10.1503/cmaj.200457 · 2020 · External reference
Projecting hospital utilization during the COVID-19 outbreaks in the United States
10.1073/pnas.2004064117 · 2020 · External reference
Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020
10.15585/mmwr.mm6915e3 · 2020 · External reference
Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020
10.15585/mmwr.mm6913e2 · 2020 · External reference
Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis
10.1136/bmj.n1412 · 2021 · External reference
A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York
2021 · External reference
Unresolved reference
External reference
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
10.1056/nejmoa2028436 · 2020 · External reference
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
10.1056/nejmoa2034577 · 2020 · External reference
Evaluation of COVID-19 vaccination strategies with a delayed second dose
10.1371/journal.pbio.3001211 · 2021 · External reference
Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants
10.1016/j.eclinm.2021.100865 · 2021 · External reference
National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
10.1056/nejmc2104974 · 2021 · External reference
Unresolved reference
2021 · External reference
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
10.1056/nejmoa2101765 · 2021 · External reference
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
10.1016/s0140-6736(21)00947-8 · 2021 · External reference
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study
10.1016/s1473-3099(21)00330-3 · 2021 · External reference
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021
10.15585/mmwr.mm7018e1 · 2021 · External reference
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
10.1056/nejmoa2101544 · 2021 · External reference
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
10.1056/nejmoa2035389 · 2021 · External reference
Seattle Is First Major U.S. City To Vaccinate 70% Of Eligible Population — Here's The Cities That Could Be Next
2021 · External reference
Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States
10.1126/scitranslmed.abh3826 · 2021 · External reference
